Testosterone Therapy for Pubertal Delay in Duchenne Muscular Dystrophy | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
active, not recruiting

Testosterone Therapy for Pubertal Delay in Duchenne Muscular Dystrophy

key information

study id #: NCT02571205

condition: Duchenne Muscular Dystrophy

status: active, not recruiting

purpose:

“Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne Muscular Dystrophy” is a single centre observational study that aims to follow the progress of 20 adolescents with Duchenne Muscular Dystrophy (DMD) and delayed puberty who are treated by the Newcastle muscle team, as they are treated with testosterone to induce puberty. The participants will all be treated with the standard stepwise regimen of testosterone injections every 4 weeks and data will be collected to help determine the effectiveness and tolerability of the current treatment regimen. The investigators will use the data to explore the effect of testosterone on pubertal development, growth, muscle strength and function, bone mineral density and body composition and characterise any side effects. Semi-structured interviews will also be carried out to learn the boys’ views on the tolerability of the regimen. The study will last up to a maximum of 27 months in total for each participant, but may be less if they are happy with pubertal development before this time. It is important to do this study because from the investigator’s limited experience in this group, testosterone treatment seems to be well liked and tolerated but the best treatment regimen to use remains unknown and there is no current consensus. It is not currently part of the standard of care in DMD but it would be important to include it if this study can show that it is an effective treatment for pubertal delay.

intervention: Sustanon (testosterone)

mechanism of action: Glucocorticoid to delay decline in muscle strength

results: https://clinicaltrials.gov/ct2/show/results/NCT02571205

last updated: November 22, 2018

study details

start date: November 2015

estimated completion: February 2019

size / enrollment: 15

primary outcomes:

  • Total score in the Treatment Satisfaction Questionnaire for Medication (TSQM) [ Time Frame: 2 years ]

secondary outcomes:

  • Subject's reported effectiveness of testosterone therapy as assessed by semi-structured interviews pre and post treatment [ Time Frame: 2 years ]
  • Total score in Northstar Ambulatory Assessment or Performance of the Upper Limb if non-ambulant [ Time Frame: 2 years ]
  • Z-score from Bone mineral adjusted density of the lumbar spine and total body (minus head) using Dual Xray Absorptiometry (DXA) [ Time Frame: 2 years ]
  • Percentage of body mass assessed by DXA [ Time Frame: 2 years ]
  • Osteocalcin level, measured by blood test [ Time Frame: 2 years ]
  • P1NP level, measured by blood test [ Time Frame: 2 years ]
  • Percentage fat fraction as assessed by muscle Magnetic Resonance Imaging (MRI) of upper and lower limbs [ Time Frame: 2 years ]
  • Pubertal staging assessed using Tanner staging and testicular volume [ Time Frame: 2 years ]
  • Bone age as assessed by wrist and hand X-Ray [ Time Frame: 2 years ]
  • Hormonal assessment of pubertal staging using testosterone level [ Time Frame: 2 years ]
  • Forced vital capacity, measured by spirometry [ Time Frame: 2 years ]
  • Cardiac function, assessed by Electrocardiogram (ECG) and echo [ Time Frame: 2 years

inclusion criteria:
• A molecular diagnosis of Duchenne Muscular Dystrophy.
• Males aged between 12 and 17 years of age at time of first dosing
• Prepubertal (Tanner stage 1, testicular volume <4 mls, initial testosterone level of <2.0 nmol/l)
• Subjects are receiving the standard of care for DMD as recommended by the NorthStar UK and TREAT-NMD guidelines
• Patients are capable of sitting upright in a wheelchair for at least an hour
• Patients have stable respiratory function. Artificial ventilation with either Bipap/continuous positive airways pressure (CPAP) or tracheostomy is not a contraindication to the study.
• Informed consent/assent signed by the patient (or parent/guardian if under 16 years of age)

exclusion criteria:
• Severe learning difficulties that would preclude them from cooperating with examination.
• Anticipated surgery during the study period.
• Symptomatic cardiac failure.
• Participants/families who may have emotional or psychological problems if recruited to a study
• Hypersensitivity to the active substance or to any of the excipients, including arachis oil or derivatives (including hypersensitivity and allergy to peanuts or soya.)
• Any contra-indication to receiving an intramuscular injection
• Any additional chronic disease that affects androgen production
• Anti-coagulant therapy
• If participation in the study is not recommended in the opinion of the investigators

study contacts

sponsor: Newcastle-upon-Tyne Hospitals NHS Trust

investigators: Michela Guglieri

locations: United Kingdom